4 citations
,
November 2021 in “Journal of The American Academy of Dermatology” Bicalutamide may reduce unwanted hair growth caused by minoxidil in women with hair loss.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
November 2022 in “The Caucasus” The document's conclusion cannot be provided because the content is not in a readable format.
January 2025 in “Journal of Materials Chemistry B” October 2024 in “Journal of the Endocrine Society” Misdiagnosis led to unnecessary treatment due to a genetic mutation affecting thyroid hormone resistance.
122 citations
,
July 1994 in “Journal of Investigative Dermatology” 62 citations
,
March 2017 in “Journal of Investigative Dermatology” Mutations in the ACTB gene cause Becker’s nevi and may lead to muscle issues in Becker’s nevus syndrome.
July 2024 in “Journal of Investigative Dermatology” Modulating the BTNL2 pathway can prevent hair loss in mice.
64 citations
,
August 2019 in “Circulation” ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
August 2024 in “Journal of Drug Delivery Science and Technology” The new minoxidil formulation could better promote hair growth for treating androgenic alopecia.
research 22
December 2023 in “Psychiatry Neurology and Medical Psychology”
11 citations
,
October 2019 in “Journal of Cancer Immunology” Combining Proton Minibeam with FLASH Radiotherapy may improve cancer treatment by reducing side effects and increasing effectiveness.
January 2023 in “Brazilian Journals Editora eBooks”
14 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” A girl with Becker naevus syndrome has a genetic variant in the ACTB gene related to her symptoms.
January 2007 in “xPharm: The Comprehensive Pharmacology Reference” May 2023 in “The Journal of Immunology” BST2 is a key marker for hair loss disease alopecia areata.
July 2005 in “CME: Your SA Journal of CPD” Botulinum toxin is a safe alternative for treating migraines without common side effects, but should be used after other treatments fail.
November 2025 in “The Journal of Immunology” BST2 is highly expressed in certain immune cells in alopecia areata, suggesting a role in the disease.
September 2023 in “Journal of the American Academy of Dermatology” 33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
50 citations
,
November 2010 in “Plastic and Reconstructive Surgery” Botox increased hair count in men with baldness and might work by improving scalp blood flow.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
68 citations
,
August 2009 in “American Journal of Medical Genetics Part A” A new classification for trichothiodystrophy helps identify genetic causes and potential treatments.
Onabotulinum toxin A may help treat trichotillomania and promote hair growth.
December 2010 in “SciVee”
July 2023 in “New phytologist” The BUZZ gene is important for root hair growth and overall root structure in the plant Brachypodium distachyon.
69 citations
,
August 2006 in “Behavior Therapy” Group behavior therapy reduces hair-pulling symptoms more than supportive therapy but has limited long-term effectiveness.
Newly designed proteins can effectively degrade specific proteins in cells, offering a promising alternative for targeted protein degradation.
9 citations
,
March 2022 in “Journal of radiation research” Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.